This review explores the cardioprotective effects of adiponectin in both type 1 and type 2 diabetes, focusing on its potential to regulate glucose metabolism and prevent cardiovascular complications.<h4>Recent findings</h4>By reviewing key studies, the article evaluates adiponectin's diverse roles and compares its effects on cardiovascular outcomes across diabetes subtypes, especially in diabetic cardiomyopathy, with an emphasis on congestive heart failure. This evidence concerns the gene ADIPOQ and congestive heart failure.